Reducing Morbidity and Mortality of Opioid Use Disorder (OUD): Cost Benefit and Patient Experience of Medications for Opioid Use Disorder (MOUD) Webinar Materials

Research around methadone and buprenorphine indicate the medications are some of the most effective tools to reduce morbidity and mortality associated with OUD. When accessible through equitable best practices, the medications contribute to life-changing results. During this webinar, Aaron Ferguson and Dr. Janan Wyatt reviewed the evidence, including the cost benefit, of MOUD, and recent research findings on how regulatory changes affect patient experience.

Learning Objectives:

• Have a baseline understanding of the evidence supporting MOUD, including the financial and social cost benefit
• Understand research and evidence from people with lived experience of how methadone and buprenorphine reduce morbidity and mortality associated with MOUD
• Gain knowledge of recent changes in MOUD regulations and impacts on patients’ experience and equitable access
• Reflect on how to apply key information to your RCORP consortium

Presenter(s):

• Dr. Janan Wyatt,PhD
• Aaron Ferguson